Immunofluorescent analysis of VCP using VCP Monoclonal antibody (5) (Product# MA3-004) shows staining in WiDr colon carcinoma cells. VCP staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing VCP (Product# MA3-004) at a dilution of 1:20-1:200 over night at 4°C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody (Product# 35552 for GAR, Product# 35503 for GAM). Images were taken at 60X magnification.
|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Yeast, Human, Not Applicable|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Synthetic peptide corresponding to residues C G(792) G S V Y T E D N D D D L Y G(806) of mouse VCP.|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1/400|
|Immunohistochemistry (Frozen) (IHC (F))||1:500|
|Immunohistochemistry (Paraffin) (IHC (P))||1:500|
|Immunoprecipitation (IP)||Assay dependent|
|Western Blot (WB)||1:2,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA3-004 detects VCP protein in human, mouse, and rat samples.
MA3-004 has successfully been used in Western blot immunoprecipitation, and immunohistochemical procedures. By Western blot, this antibody detects an ~97 kDa protein representing VCP from total lysate of cultured human B cells.
The MA3-004 immunogen is a synthetic peptide corresponding to residues C G(792) G S V Y T E D N D D D L Y G(806) of mouse VCP. This peptide (Cat. # PEP-239) is available for use in neutralization and control experiments.
Valosin-containing protein (VCP or p97) belongs to the AAA (ATPase associated activities) family and acts as a molecular chaperone to a wide variety of cellular activities. Some of these activities include the alteration of both nuclear and mitotic golgi membranes, ubiquitin-proteasome dependent protein degradation, regulation of the NF-kappa b pathway, and extraction of membrane proteins.
VCP has been shown to contain a substrate binding domain (N) and two conserved ATPase domains (D1 and D2). The three dimensional structure of VCP resembles that of a cylinder with the D1 and D2 stacked upon one another in a homo-hexameric ring formation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Pathogenic Mutations in the Valosin-containing Protein/p97(VCP) N-domain Inhibit the SUMOylation of VCP and Lead to Impaired Stress Response.
MA3-004 was used in western blot to assess inhibition of the SUMOylation of VCP that leads to impaired stress response by pathogenic mutations in the valosin-containing protein/p97(VCP) N-domain
|Wang T,Xu W,Qin M,Yang Y,Bao P,Shen F,Zhang Z,Xu J||The Journal of biological chemistry (291:14373)||2016|
The Myoblast C2C12 Transfected with Mutant Valosin-Containing Protein Exhibits Delayed Stress Granule Resolution on Oxidative Stress.
MA3-004 was used in immunocytochemistry and western blot to research delayed stress granule resolution on oxidative stress from myoblast C2C12 transfected with mutant valosin-containing protein
|Rodriguez-Ortiz CJ,Flores JC,Valenzuela JA,Rodriguez GJ,Zumkehr J,Tran DN,Kimonis VE,Kitazawa M||The American journal of pathology (186:1623)||2016|
Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function.
MA3-004 was used in western blot to study the roles of autophagy and Cdc48/VCP in the clearance of eukaryotic stress granules and the significance for neurodegenerative disease
|Buchan JR,Kolaitis RM,Taylor JP,Parker R||Cell (153:1461)||2013|
SEL1L protein critically determines the stability of the HRD1-SEL1L endoplasmic reticulum-associated degradation (ERAD) complex to optimize the degradation kinetics of ERAD substrates.
MA3-004 was used in western blot to investigate the stability of mammalian HRD1-SEL1L complex and the regulatory machinery of its stability and assembly
|Iida Y,Fujimori T,Okawa K,Nagata K,Wada I,Hosokawa N||The Journal of biological chemistry (286:16929)||2011|
Different p97/VCP complexes function in retrotranslocation step of mammalian ER-associated degradation (ERAD).
MA3-004 was used in western blot to investigate the role of different p97/VCP complexes in Hrd1- and gp78-mediated mammalian endoplasmic reticulum-associated degradation
|Ballar P,Pabuccuoglu A,Kose FA||The international journal of biochemistry and cell biology (43:613)||2011|
Differential regulation of CFTRDeltaF508 degradation by ubiquitin ligases gp78 and Hrd1.
MA3-004 was used in western blot to investigate the role of gp78 and Hrd1 ubiquitin ligases in the degradation of cystic fibrosis transmembrane conductance regulator with the deletion of phenylalanine 508
|Ballar P,Ors AU,Yang H,Fang S||The international journal of biochemistry and cell biology (42:167)||2010|
Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications.
MA3-004 was used in western blot to study the effect of endoplasmic reticulum-associated degradation inhibition on DeltaF508-cystic fibrosis transmembrane regulator and interleukin-8.
|Vij N,Fang S,Zeitlin PL||The Journal of biological chemistry (281:17369)||2006|
Ubiquitin-negative, eosinophilic neuronal cytoplasmic inclusions associated with stress granules and autophagy: an immunohistochemical investigation of two cases.
MA3-004 was used in immunohistochemistry to investigate the association of eosinophilic neuronal cytoplasmic inclusions with stress granules and autophagy in two clinical cases
|Mori F,Watanabe Y,Miki Y,Tanji K,Odagiri S,Eto K,Wakabayashi K||Neuropathology : official journal of the Japanese Society of Neuropathology (34:140)||2014|
Valosin-containing protein immunoreactivity in tauopathies, synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease.
MA3-004 was used in immunohistochemistry to study the presence of structures containing VCP in the brains from 72 patients with a range of neurodegenerative diseases
|Mori F,Tanji K,Toyoshima Y,Sasaki H,Yoshida M,Kakita A,Takahashi H,Wakabayashi K||Neuropathology : official journal of the Japanese Society of Neuropathology (33:637)||2013|
Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice.
MA3-004 was used in immunohistochemistry and immunoprecipitation to study the effect of valosin-containing protein mutations on ubiquitin and TDP-43 accumulation and cognitive function in mice
|Rodriguez-Ortiz CJ,Hoshino H,Cheng D,Liu-Yescevitz L,Blurton-Jones M,Wolozin B,LaFerla FM,Kitazawa M||The American journal of pathology (183:504)||2013|
|Not Applicable||Not Cited||
Amyotrophic lateral sclerosis (ALS)-associated VAPB-P56S inclusions represent an ER quality control compartment.
MA3-004 was used in immunohistochemistry to determine ER quality control compartments created by amyotrophic lateral sclerosis (ALS)-associated VAPB-P56S inclusions
|Kuijpers M,van Dis V,Haasdijk ED,Harterink M,Vocking K,Post JA,Scheper W,Hoogenraad CC,Jaarsma D||Acta neuropathologica communications (1:null)||2013|
Nuclear localization of valosin-containing protein in normal muscle and muscle affected by inclusion-body myositis.
MA3-004 was used in immunohistochemistry to investigate the role of valosin-containing protein in inclusion-body myopathy with Paget disease and frontotemporal dementia
|Greenberg SA,Watts GD,Kimonis VE,Amato AA,Pinkus JL||Muscle and nerve (36:447)||2007|